Techcyte, OptiPath expand digital pathology workflow in Germany

Techcyte said Germany-based OptiPath has implemented the Fusion platform for cytology and histology workflows, including the SureView cervical cytology system. The move comes as OptiPath prepares for higher gynecological cytology volume tied to Germany’s triennial screening program.

Why it matters: - OptiPath is consolidating cytology and histology work inside one digital pathology environment. - The deployment is aimed at handling rising gynecological cytology volume in Germany’s screening program. - Techcyte is positioning Fusion as a single platform for both anatomic and clinical pathology.

What happened: - Techcyte announced that OptiPath, a Germany-based pathology laboratory, has implemented the Techcyte Fusion platform for cytology and histology workflows. - The deployment includes Techcyte SureView Cervical Cytology System, which is distributed globally in partnership with Waters Corporation. - Waters Corporation recently acquired Becton Dickinson’s Biosciences & Diagnostic Solutions business. - OptiPath processes a significant number of gynecological cytology samples each year. - Techcyte said 2026 volumes are expected to rise because Germany’s screening program follows a triennial recurring structure.

The details: - OptiPath adopted Fusion to bring digital cervical cytology workflows supported by Techcyte SureView and histology case management through Fusion AP into one environment. - Techcyte Fusion integrates image management, case workflows, reporting and AI-enabled tools within a single system. - Techcyte said Fusion is the only platform that supports both anatomic and clinical pathology. - Dr. Riener, Co-Owner and Head Cytologist at OptiPath, said implementing a digital platform across cytology and histology was a considered and necessary step for the laboratory. - Dr. Riener said increased case volume from the screening program made structured workflow and review of both disciplines in a common environment more relevant.

Between the lines: - The deployment suggests labs are moving from separate workflows toward unified digital review systems. - The combination of cytology and histology in one platform may help labs standardize operations as screening-driven volumes change. - Techcyte is using the OptiPath rollout to underscore Fusion’s broader positioning in digital pathology.

What's next: - OptiPath will use the Fusion platform as gynecological cytology volumes rise in 2026. - Techcyte is likely to point to the deployment as another example of multi-workflow adoption across pathology labs. - The company directs readers to more information on its website.

The bottom line: - OptiPath’s adoption gives Techcyte another reference point for its unified digital pathology platform, while giving the German lab a single workflow for cytology and histology.